These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 12109923)

  • 1. Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis.
    Nurmohamed MT; van Halm VP; Dijkmans BA
    Drugs; 2002; 62(11):1599-609. PubMed ID: 12109923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs for the treatment of rheumatoid arthritis.
    Schuna AA; Megeff C
    Am J Health Syst Pharm; 2000 Feb; 57(3):225-34. PubMed ID: 10674776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoarthritis therapy--are there still unmet needs?
    Laufer S
    Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i9-15. PubMed ID: 14752170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis.
    Bae SC; Corzillius M; Kuntz KM; Liang MH
    Rheumatology (Oxford); 2003 Jan; 42(1):46-53. PubMed ID: 12509612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
    Harley C; Wagner S
    Clin Ther; 2003 Jan; 25(1):139-49. PubMed ID: 12637116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea.
    Lee MC; Lee S; Suh DC; Kim J; Kong SX;
    Curr Med Res Opin; 2003; 19(7):597-602. PubMed ID: 14606981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cyclooxygenase 2 selective antirheumatic analgesics].
    Aringer M
    Wien Med Wochenschr; 2003; 153(5-6):100-3. PubMed ID: 12705062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the treatment of rheumatoid arthritis: old versus new therapies.
    Saravanan V; Hamilton J
    Expert Opin Pharmacother; 2002 Jul; 3(7):845-56. PubMed ID: 12083985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative safety of traditional non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors].
    Bannwarth B
    Presse Med; 2002 Dec; 31(39 Pt 2):4S7-9. PubMed ID: 12518070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controversies in COX-2 inhibitor therapy: closing remarks.
    Abramson SB; Furst DE; Hochberg MC; Patrono C
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S77-80. PubMed ID: 11695257
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical experience with cyclooxygenase-2 inhibitors.
    Lanas A
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():16-22; discussion 35-42. PubMed ID: 12173276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of selective cyclooxygenase-2 inhibition.
    Emery P
    Scand J Rheumatol Suppl; 1996; 102():23-8. PubMed ID: 8628978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?
    Savage R
    Drugs Aging; 2005; 22(3):185-200. PubMed ID: 15813652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arthritis. Timely treatments for an ageless disease.
    Lewis C
    FDA Consum; 2000; 34(3):27-9, 31-3. PubMed ID: 11521251
    [No Abstract]   [Full Text] [Related]  

  • 19. [Is there a future for COX-2 inhibitors?].
    Yodfat Y
    Harefuah; 2004 Nov; 143(11):820-4, 837. PubMed ID: 15603272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COX-2 inhibitors.
    Brooks PM; Day RO
    Med J Aust; 2000 Oct; 173(8):433-6. PubMed ID: 11090038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.